Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study

NCT02619435 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT02619435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02619435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2015
Completion date
November 30, 2024
Enrollment
46 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced colorectal cancer